These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6419110)

  • 21. [Continuous subcutaneous insulin infusion].
    Araki H; Makino H; Yoshida S
    Nihon Rinsho; 1990 Dec; 48 Suppl():1038-43. PubMed ID: 2086865
    [No Abstract]   [Full Text] [Related]  

  • 22. No sign of amyloidosis in pump-treated diabetics.
    Regal H; Koivisto VA; Maury CP; Irsigler K
    Diabetes Res; 1988 Aug; 8(4):195-9. PubMed ID: 3069282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid").
    Campbell IW; Kritz H; Najemnik C; Hagmueller G; Irsigler K
    Diabetes Res; 1984 Jul; 1(2):83-8. PubMed ID: 6442226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events.
    Cope JU; Morrison AE; Samuels-Reid J
    Pediatrics; 2008 May; 121(5):e1133-8. PubMed ID: 18450857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of insulin-dependent diabetes mellitus by insulin pump in children under 7 years of age].
    Joseph MG; Ginies JL; Chomienne F; Limal JM
    Arch Fr Pediatr; 1992; 49(6):505-10. PubMed ID: 1449351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient management of long-term continuous subcutaneous insulin infusion.
    Johansson UB; Adamson U; Lins PE; Wredling R
    J Adv Nurs; 2005 Jul; 51(2):112-8. PubMed ID: 15963182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy.
    Earle K; Walker J; Hill C; Viberti G
    N Engl J Med; 1992 Mar; 326(10):673-7. PubMed ID: 1736105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sudden death due to diabetic ketoacidosis following power failure of an insulin pump: Autopsy and pump data.
    Kjærulff MLBG; Astrup BS
    J Forensic Leg Med; 2019 Apr; 63():34-39. PubMed ID: 30856551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malfunction of continuous subcutaneous insulin infusion systems: a one-year prospective study of 127 patients.
    Mecklenburg RS; Guinn TS; Sannar CA; Blumenstein BA
    Diabetes Care; 1986; 9(4):351-5. PubMed ID: 3743310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Problems and safety of continuous subcutaneous insulin infusion.
    Home PD; Marshall SM
    Diabet Med; 1984 May; 1(1):41-4. PubMed ID: 6242775
    [No Abstract]   [Full Text] [Related]  

  • 32. [Continuous subcutaneous insulin infusion].
    Iwaoka H; Makino H; Yoshida S
    Nihon Rinsho; 1989 Nov; 47(11):2577-82. PubMed ID: 2601069
    [No Abstract]   [Full Text] [Related]  

  • 33. Fatalities Due to Failure of Continuous Subcutaneous Insulin Infusion Devices: A Report of Six Cases.
    Ziegler A; Williams T; Yarid N; Schultz DL; Bundock EA
    J Forensic Sci; 2019 Jan; 64(1):275-280. PubMed ID: 29940703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients.
    Mecklenburg RS; Benson EA; Benson JW; Fredlund PN; Guinn T; Metz RJ; Nielsen RL; Sanner CA
    JAMA; 1984 Dec; 252(23):3265-9. PubMed ID: 6439896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported experience with Velosulin human insulin in continuous subcutaneous insulin infusion.
    Marcus A; Bode B; Drexler A; Etkind E; Koch MM; Liljenquist JE; McCulloch DK; Strowig SM; Tanenberg RJ
    Clin Ther; 1995; 17(2):204-13. PubMed ID: 7614521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute complications associated with the use of insulin infusion pumps.
    Mecklenburg RS
    Diabetes Educ; 1989; 15(1):40-3. PubMed ID: 2491989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deaths among patients using continuous subcutaneous insulin infusion pumps - United States.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Feb; 31(7):80-2, 87. PubMed ID: 6801463
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin infusion therapy. Potential benefits and risks.
    Bonner RA
    Postgrad Med; 1985 May; 77(6):153-64. PubMed ID: 3921945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possibility to reduce mortality in diabetic ketoacidosis.
    Rosival V
    Diabetes Technol Ther; 2013 Sep; 15(9):786. PubMed ID: 23931740
    [No Abstract]   [Full Text] [Related]  

  • 40. Possibility to reduce diabetic ketoacidosis-related mortality in type 1 diabetes: prevention versus treatment.
    Realsen J; Goettle H; Chase HP
    Diabetes Technol Ther; 2013 Sep; 15(9):787. PubMed ID: 23931741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.